Objective. To evaluate proinflammatory cytokines and leukocyte subpopulations in the cerebrospinal fluid (CSF) and blood of patients with neonatal-onset multisystem inflammatory disease (NOMID) after treatment, and to compare inflammatory cytokines in the CSF and blood in 6 patients treated with 2 interleukin-1 (IL-1) blockers-anakinra and canakinumab.
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Objective. To evaluate proinflammatory cytokines and leukocyte subpopulations in the cerebrospinal fluid (CSF) and blood of patients with neonatal-onset multisystem inflammatory disease (NOMID) after treatment, and to compare inflammatory cytokines in the CSF and blood in 6 patients treated with 2 interleukin-1 (IL-1) blockers-anakinra and canakinumab.
Methods. During routine follow-up visits between December 2011 and October 2013, we immunophenotyped the CSF of 17 pediatric NOMID patients who were treated with anakinra, and analyzed CSF cytokine levels in samples obtained at baseline and at 3-5-year follow-up visits and compared them to samples from healthy controls.*
Results. CSF levels of IL-6, interferon-g-inducible 10-kd protein (IP-10/CXCL10), and IL-18 and monocyte and granulocyte counts significantly decreased with anakinra treatment but did not normalize to levels in the controls, even in patients fulfilling criteria for clinical remission. CSF IL-6 and IL-18 levels significantly correlated with measures of blood-brain barrier function, specifically CSF protein (r 5 0.75 and r 5 0.81, respectively) and albumin quotient (r 5 0.79 and r 5 0.68, respectively). When patients were treated with canakinumab versus anakinra, median CSF white blood cell counts and IL-6 levels were significantly higher with canakinumab treatment (10.2 cells/mm 3 versus 3.7 cells/mm 3 and 150.7 pg/ml versus 28.5 pg/ml, respectively) despite similar serum cytokine levels.
Conclusion. CSF leukocyte subpopulations and cytokine levels significantly improve with optimized IL-1 blocking treatment, but do not normalize. The correlation of CSF IL-6, IP-10/CXCL10, and IL-18 levels with clinical laboratory measures of inflammation and blood-brain barrier function suggests that they may have a role as biomarkers in central nervous system (CNS) inflammation. The difference in inhibition of CSF biomarkers between 2 IL-1 blocking agents, anakinra and canakinumab, suggests differences in efficacy in the intrathecal compartment, with anakinra being more effective. Our data indicate that intrathecal immune responses shape CNS inflammation and should be assessed in addition to blood markers.
Neonatal-onset multisystem inflammatory disease (NOMID), also referred to as chronic infantile neurologic, cutaneous, articular syndrome, is the most severe clinical form of the disease spectrum of cryopyrinassociated periodic syndromes (CAPS). CAPS are caused by gain-of-function mutations in the NLRP3 gene that encodes cryopyrin, a protein that is expressed in hematopoietic cells including granulocytes, monocytes, dendritic cells, and nonhematopoietic cells that include microglial and reactive astrocytes in the central nervous system (CNS) (1-3). Two-thirds of patients with NOMID have de novo germline mutations and ;30% have somatic mosaicism in NLRP3 (4). Pathogenic NLRP3 mutations lead to constitutive inflammasome activation with secretion of interleukin-1b (IL-1b) and to moderate elevations in levels of .
CAPS patients present with episodic (on the milder end of the disease spectrum) or continuous (on the more-severe end of the spectrum) systemic inflammation that includes recurrent fever flares with neutrophilic urticaria, arthralgia, and increased levels of acute-phase reactants. With increasing severity of CAPS, CNS and organ inflammation become more prevalent and chronic, which leads to organ damage. Cochlear inflammation leads to sensorineural hearing loss, chronic papilledema leads to optic nerve atrophy and peripheral visual field loss, and chronic increased intracranial pressure can lead to brain atrophy and mental retardation. These features are commonly observed in patients with NOMID, and are more variable or absent in the milder forms of CAPS (Muckle-Wells syndrome and familial cold autoinflammatory disease, respectively) (5, 6) .
Treatment with IL-1 blocking agents results in significant clinical and laboratory improvements in NOMID and has become the standard of care. NOMID patients with germline or somatic mosaicism do not differ in disease severity and respond equally to IL-1 blocking treatment (4, 7) . Anakinra can penetrate into the CNS and treatment improves CNS inflammation by decreasing cerebrospinal fluid (CSF) pleocytosis, opening pressure and protein levels, papilledema, and inner ear enhancement (6) (7) (8) . It currently remains unclear whether adequate inflammatory control is achieved in NOMID patients with severe CNS inflammation receiving treatment with both short-acting (anakinra) and long-acting (canakinumab and rilonacept) IL-1 inhibitors. We have observed that normalization of acute-phase reactant levels in the blood does not preclude persistent, low-grade CNS pleocytosis (suggesting ongoing CNS inflammation) (4, 9) , and that dose escalations of the IL-1 blocking agent anakinra, beyond levels needed to control peripheral inflammation, are needed to optimally control CNS inflammation (7) .
In a previous study we observed that IL-6 levels in the CSF of untreated NOMID patients were on average 6 times higher than IL-6 levels in the blood (6), suggesting that IL-6 may be produced in the CNS by resident cells, as suggested in CNS inflammation in patients with systemic lupus erythematosus (10) and in those with neuro-Behçet's syndrome (2) . However, correlations of IL-6 levels with mononuclear cell subsets in the CSF (6), or their use as a potential biomarker for CNS disease in NOMID, have yet to be assessed.
In the present study we evaluated 9 cytokines (including IL-6) in the CSF compared to serum and determined the correlation between cytokine levels and blood-brain barrier function and CNS inflammation to assess their use as biomarkers for CNS inflammation. We further compared cytokine levels in 6 patients who sequentially received anakinra and canakinumab.
PATIENTS AND METHODS
Patients and controls. Between December 2011 and October 2013, we collected (for immunophenotyping) CSF samples from 17 consecutive anakinra-treated pediatric NOMID patients who were enrolled in a natural history and treatment study (NCT00069329) and had returned for routine follow-up. For the cytokine analyses, we used archived CSF and plasma/serum samples that were collected, spun, and frozen from baseline (before patients received IL-1 blocking treatments) and follow-up (after patients started IL-1 blocking treatments). We immunophenotyped CSF leukocyte subsets on freshly collected samples (11) . One patient was excluded from the analyses of cell populations due to a technical problem with the staining procedure (see Supplementary Figures 1A and 1B, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40055/abstract).
Archived baseline (prior to anakinra treatment) and posttreatment paired CSF and serum samples were available for 11 of the 17 patients. For the cytokine analyses we included samples from 4 additional patients with NOMID for whom matched baseline and posttreatment CSF and serum samples had been stored, but whose CSF had not been immunophenotyped for cell subsets (see Supplementary Figures 1A and B, http://onlinelibrary.wiley.com/doi/10.1002/art. 40055/abstract).
Complete clinical remission was defined by the following criteria: erythrocyte sedimentation rate (ESR) #25 mm/hour, C-reactive protein (CRP) #0.5 mg/dl, CSF white blood cell (WBC) count #5 cells/mm 3 , and protein #40 mg/dl (7) . Blood plasma/serum and CSF samples from patients with NOMID were compared to serum samples from 11 pediatric agematched controls and to 7 CSF samples, respectively. Five of the CSF samples were from healthy adult controls recruited for another study (11) , and 2 were from pediatric patients with undifferentiated autoinflammation who had undergone a diagnostic lumbar puncture but had no evidence of CNS inflammation according to medical history, imaging, and CSF markers (leukocytosis, opening pressure, and protein content).
Longitudinal cytokine analyses of all available CSF and serum samples were conducted for 21 patients (see Supplementary Figure 1B , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40055/ abstract). To assess the relevance of these biomarkers longitudinally, we included 6 patients who were initially treated with anakinra and subsequently switched to canakinumab (9) .* Three of the 6 patients were ultimately switched back to anakinra.
Written informed consent was obtained from all patients and/or their legal guardians. The current study was conducted in accordance with the Declaration of Helsinki, and the local institutional review board approved the protocol.
Assessment of clinical laboratory CSF parameters. CSF WBC counts were assessed in the NIH clinical laboratory (from unspun CSF) and in the laboratory of one of the authors (BB) (from spun and 50-fold concentrated CSF), as described (11) . Where applicable, CSF and serum samples were utilized to ascertain routine CSF protein and glucose levels, calculated CSF/serum albumin quotients, and IgG index to assess bloodbrain barrier function (12) . , tumor necrosis factor [TNF], IL-1a, IL-18, and IFN-a2) were assessed via Bio-Plex multiplex assays (Bio-Rad), as previously reported (13) . Samples were stored at 2808C and the majority (except for some baseline blood and CSF samples) had not been previously thawed. Of the cytokines assessed, 5 were not included in the tables or further analyzed (see Supplementary Table 1A , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40055/abstract), including 2 that were undetectable in most of the CSF samples (IFN-a2, IL1a), 2 whose levels were not significantly different from those in controls and did not change with treatment (IL-9, IL12p40), and 1 with levels lower than in controls, with significant variability and no change with treatment (IL-17).
Immunophenotyping of leukocytes. We analyzed absolute values of 5 subpopulations of leukocytes, which included monocytes, granulocytes, natural killer cells, CD31 cells, and B cells. Sample preparation and immunophenotyping of leukocytes by flow cytometry were performed as previously reported (11) .
Correlation analyses. Correlations of CSF and blood cytokine levels with leukocyte subpopulations were mostly analyzed posttreatment; CSF and blood immunophenotyping were performed prior to initiation of IL-1 blocking therapy in only 2 patients. CSF cytokine levels were also correlated with the following parameters of inflammation in CSF: CSF opening pressures, WBC count, total protein, and albumin quotient.
Two of the 21 patients had ventriculoperitoneal shunts and were excluded only from CSF inflammation parameter correlations; both had very high protein levels at baseline, consistent with decreased circulation of spinal cord CSF related to the mechanical shunt (14) .
Statistical analysis. Statistical analyses and graphing were performed using GraphPad 6 and Stata (StataCorp) software. Differences between nonpaired data with parametric or nonparametric distributions were analyzed using Student's t-test and Wilcoxon's rank sum test, respectively. Paired CSF and blood samples were analyzed with Student's paired t-test using log 10 transformation of raw values. Correlations were assessed with Spearman's correlation coefficient. Due to the pilot nature of the study, we provided raw P values, unadjusted for multiple comparisons. (9) has been added to this sentence.
RESULTS
Demographic and clinical characteristics. The mean 6 SD age of the NOMID patients at study enrollment was 6.3 6 5.7 years. Nineteen of 23 patients had germline NLRP3 mutations and 4 had somatic mosaicism (Table 1) . At baseline, most patients had been receiving treatment with disease-modifying antirheumatic drugs (DMARDs) and/or steroids. Patients whose disease was in complete clinical remission who had been treated with anakinra had received a mean 6 SD dosage of 4.6 6 1.4 mg/kg/day and had been receiving treatment for 2.8 6 2.8 years, compared to patients receiving anakinra whose disease was improved but not in complete remission, who had received an average dosage of 3.4 6 1.4 mg/kg/day and were being treated with anakinra for 1.6 6 1.3 years.* None of the patients were taking steroids or DMARDs posttreatment, except for 1 patient who was receiving methotrexate at the time of the sample collection.
Decrease in CSF and blood cytokine levels with IL-1 blocking treatment. Baseline CSF levels of IL-18, IL-6, and IP-10/CXCL10 were significantly higher in NOMID patients compared to healthy controls (median 12.07 pg/ml versus 0.29 pg/ml, 555.31 pg/ml versus 5.61 pg/ml, and 8,239.0 pg/ml versus 544.19 pg/ml, respectively), but there was no statistically significant difference in Figure 1 . Cytokine levels in cerebrospinal fluid (CSF) from patients with neonatal-onset multisystem inflammatory disease at baseline (base), when disease was not in clinical remission (not CR), and when disease was in complete clinical remission. Paired CSF samples were analyzed by Student's paired t-test using log 10 transformation of raw values. Unpaired comparisons were performed by Student's unpaired t-test or Wilcoxon's rank sum test, depending on data distribution. Symbols represent individual patients; bars show the median. * 5 P , 0.05; ** 5 P , 0.005. IL-1Ra 5 interleukin-1 receptor antagonist; TNF 5 tumor necrosis factor; IFNg 5 interferon-g; IP-10 5 interferon-g-inducible 10-kd protein.
* Correction added on May 19, 2017, after online publication: 1.7 years was changed to 2.8 years in this sentence.
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RODRIGUEZ-SMITH ET AL blood levels of IP-10 in healthy controls versus patients (Figures 1 and 2 ). In contrast, CSF levels of IL-12p70 were significantly lower in patients versus healthy controls, and levels of TNF, IFNg, and IL-10 in the CSF were not significantly different between the 2 groups ( Figure 1 ). CSF IL-6 and IP-10/CXCL10 levels significantly decreased in patients receiving anakinra treatment (to a median of 17.5 pg/ml for IL-6 and 2,567.5 pg/ml for IP-10). CSF IL-6 levels were significantly lower in patients who were considered to have met criteria for clinical remission compared to those who had received treatment but had not met the criteria, but remained elevated compared to levels in healthy controls ( Figure 1 ). CSF IL-18 levels decreased, particularly in patients with baseline IL-18 levels of .20 pg/ml, but this decrease was not statistically significant. Levels of IL-1b, TNF, IL-12p70, IFNg, and IL-10 in the CSF were elevated compared to baseline levels (significantly for IL-12p70, IFNg, and IL-10). This elevation reached statistical significance in patients who met the criteria for clinical remission compared to healthy controls (IL-1b 0.8 pg/ml versus 0. Similar to levels in the CSF, baseline blood levels of IL-18 and IL-6 were significantly higher in untreated Figure 2 . Cytokine levels in blood from patients with neonatal-onset multisystem inflammatory disease at baseline, when disease was not in clinical remission, and when disease was in complete clinical remission. Paired blood samples were analyzed by Student's paired t-test using log 10 transformation of raw values. Unpaired comparisons were performed by Student's unpaired t-test or Wilcoxon's rank sum test, depending on data distribution. Symbols represent individual patients; bars show the median. * 5 P , 0.05; ** 5 P , 0.005. For IL-6 levels, n 5 10 controls. See Figure 1 for definitions.
NOMID patients than in controls (median 538.9 pg/ml versus 70.4 pg/ml [P 5 0.002] and 65.3 pg/ml versus 22.0 pg/ml [P 5 0.002], respectively) and decreased with treatment, but remained significantly higher relative to levels in healthy controls (Figure 2 ). Unlike levels in the CSF, baseline blood levels of IP-10/CXCL10 in patients were similar to levels in healthy controls. IL-12p70 levels, although lower in the CSF of patients with NOMID versus controls, were significantly higher in the blood of NOMID patients versus controls. Blood levels of IL12p70 remained stable in patients receiving anakinra, while blood TNF, IL-10, and IFNg levels increased (significantly for TNF and IL-10). Blood IP-10 levels remained unchanged with treatment. As we expected, after anakinra treatment, blood and CSF levels of IL1Ra increased (as they reflect a sum of both endogenous 
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RODRIGUEZ-SMITH ET AL and recombinant IL-1Ra or anakinra). IL-1b levels, which have been found only at very low levels in patients with NOMID (6), did not significantly increase.
To compare the amount of cytokine production in the CNS compared to the blood, matched CSF and blood samples were analyzed for cytokine CSF:blood ratios in the same assay, with appropriate serum and CSF controls. Consistent with results found in a previous study (6) , baseline IL-6 levels were higher in the CSF than in blood samples; this was also observed for IP-10 levels in the CSF. Median CSF:blood ratios in patients were 31-and 11-fold higher than those in controls, with a median CSF:blood ratio of 5.2 for IL-6, and 8.7 for IP-10/CXCL10 (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40055/ abstract). The CSF:blood ratios for IL-6 and IP-10/ CXCL10 progressively decreased with treatment and were lowest when disease was in clinical remission (0.5 and 1.2, respectively). The median CSF:blood ratios for the other cytokines (including IL-1b and IL-18) demonstrated lower levels in the CSF than in the blood (with ratios between 0.05 and 0.2) and did not significantly change with anakinra treatment, except that the IL-12p70 and IFNg CSF:blood ratios increased (though not significantly) after treatment (due to a greater increase in the CSF than in blood levels).
Significant decrease in CSF monocyte and granulocyte counts, but no full normalization, during remission. Patients with NOMID have a predominant elevation of innate leukocytes in the CSF (11) . Although adaptive immune cells (CD31 cells and B cells) are mildly increased in the CSF of untreated and anakinra-treated patients, only numbers of innate immune cells (monocytes, granulocytes) were significantly higher in patients with NOMID compared to controls (Figure 3 ). Monocyte and granulocyte numbers decreased posttreatment, but monocyte numbers remained on average 3-fold higher in patients with NOMID who were treated with anakinra in comparison to controls, while neutrophils remained only ;1.5-fold higher in anakinra-treated NOMID patients versus controls For each patient, baseline data (green; n 5 7) were used if available and posttreatment data (black; n 5 12) if baseline data were not available (total of 19 patients). Two patients were excluded because they had ventricular peritoneal shunts. Correlation coefficients and P values were assessed using Spearman's correlation coefficient. Non-linear regression robust straight lines are shown in each graph. WBC 5 white blood cells (see Figure 1 for other definitions). Figure 5 . IL-6, IP-10/CXCL10, and IL-18 levels in the CSF of 6 pediatric neonatal-onset multisystem inflammatory disease patients who received anakinra and canakinumab in sequence. All 6 patients initially received anakinra and were then switched to canakinumab. After canakinumab, 3 patients' treatments were switched back to anakinra. Plus signs indicate baseline samples. $5 patients with otitis media or sinusitis at time of procedure. * 5 patient was taking one-fourth of the prescribed dose. ND 5 not done due to no or insufficient CSF sample (see Figure 1 for other definitions).
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RODRIGUEZ-SMITH ET AL (P not significant). B cell counts remained stable, and CD31 T cell counts increased significantly (;3-4-fold) with treatment.
Significant correlation of CSF IL-6 and IP-10/ CXCL10 levels with monocyte counts during clinical remission. To investigate associations between inflammatory cells and cytokines, we analyzed correlations between CSF cytokine levels and CSF leukocyte subpopulations. Posttreatment, only CSF IL-6 levels correlated significantly with the number of CSF monocytes (r 5 0.51, P 5 0.046). When the illness was in remission, this correlation became stronger (r 5 0.88, P 5 0.004), and IP-10/CXCL10 levels also correlated significantly with CSF monocytes (r 5 0.81, P 5 0.015) (see Supplementary Tables 1B and C, available Increased within-patient CSF cytokine levels and CSF WBC counts when treated with "optimized" doses of canakinumab versus anakinra. To date, there are no published comparative studies comparing anakinra and the long-acting anti-IL-1b monoclonal antibody canakinumab for treatment of CNS inflammation. Since CSF IL-6, IP-10, and IL-18 levels correlated with clinical measures including monocyte counts and bloodbrain barrier function in anakinra-treated patients with NOMID, we assessed serial CSF and blood IL-6, IP-10/ CXCL10, and IL-18 levels as well as CNS inflammatory markers in 6 pediatric patients who were initially treated with anakinra and were then switched to canakinumab. Three of these patients were switched back to anakinra ( Figure 5 ). We found that CSF IL-6, IP-10/CXCL10, and IL-18 levels and WBC counts were significantly higher when patients were receiving canakinumab than when they were receiving anakinra (Table 2), despite only infrequent self-reports of headaches. The CSF cytokine levels and the WBC counts decreased in the 3 patients who switched back to anakinra after canakinumab treatment (see Figures 5B-D and Supplementary  Tables 3B-D, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40055/abstract); however, these results did not reach statistical significance due to the small number of patients. In patients receiving either anakinra or canakinumab treatment, ESRs and CRP levels were normal and blood IL-6, IP-10/CXCL10, and IL-18 levels did not significantly differ between treatments (see Table 2 and Supplementary Tables 3A-F, http://onlinelibrary.wiley. com/doi/10.1002/art.40055/abstract).
DISCUSSION
Increased NLRP3 inflammasome assembly and IL-1b secretion cause the systemic disease manifestations of NOMID. However, the regulation of CNS inflammation, the contribution of CNS resident cells to the development of chronic aseptic meningitis and brain damage, and differences in the effects of various IL-1 blocking treatments on CNS inflammation remain unknown. Our data indicate that IL-6 and IP-10/CXCL10 levels are highly elevated in the CSF and decreased with treatment, but did not normalize in all patients. Furthermore, IL-18, IL-6, and IP-10/CXCL10 may be markers for bloodbrain barrier function, and differences in treatment responses to the 2 IL-1 blocking agents anakinra and canakinumab suggest differences in CNS penetration. Collectively, our data suggest a role of serial CSF biomarker measurements in assessing and monitoring residual CNS inflammation in patients with NOMID receiving different IL-1 blocking treatments.
Elevated granulocyte counts, which represent .90% of abnormally elevated cell numbers in the CSF of untreated NOMID patients with aseptic meningitis, virtually normalized with IL-1 blocking treatment. In contrast, CSF monocyte levels decreased but remained significantly elevated even in patients with illness in clinical remission. Of the 9 inflammatory cytokines we examined to characterize potential low-grade inflammation, only IL-6 and IP-10/CXCL10 were expressed at higher levels in the CSF compared to corresponding serum samples; the levels of both cytokines were significantly lower (albeit not completely normalized) with anakinra treatment compared to canakinumab. Levels were lowest when patients' disease was in clinical remission compared to those in patients who were receiving treatment but did not fulfill clinical remission criteria. The presence of higher levels of IL-6 and IP-10 in the CSF compared to the blood suggests production of these cytokines in the CNS. Although monocytes in the CSF can produce IL-1, microglia and astrocytes can produce IL-6 and IP-10 in response to IL-1b during active disease and are a likely source for the cytokine production in the CNS in NOMID (15) .
IP-10/CXCL10 is a known downstream marker of IFN signaling, and levels of IP-10/CXCL10 in the blood of patients with NOMID are not elevated above control levels. In contrast, levels of IP-10/CXCL10 in the blood are highly elevated in patients with IFNmediated autoinflammatory diseases (16, 17) . While it is necessary to further evaluate the mechanisms that lead to elevation of IP-10/CXCL10 levels in the CSF but not the blood of untreated NOMID patients, IFN-and STAT-1-independent mechanisms of IP-10/CXCL10 up-regulation have been observed in astrocytes and microglia in the CNS in a murine HIV model (18) . IP-10/CXCL10 production has also been observed in brain microvascular endothelial cells that form the bloodbrain barrier in response to exposure to serum from patients with neuromyelitis optica (19) . These observations raise the question of whether the elevation of IP-10/CXCL10 levels in the CSF may reflect astrocyte, microglial, and/or brain microvascular endothelial cell activation in response to blood-brain barrier damage in NOMID.
In contrast to IL-6, IP-10/CXCL10, and IL-18 levels, which all decreased with treatment, we observed small but significant increases in the levels of TNF, IL12p70, IL-10, and IFNg in the CSF with treatment (in the context of significant clinical improvement). The overall levels of these cytokines were much lower in the CSF than in the blood (10 pg/ml for TNF, IL-12p70, and IL-10, and 150 pg/ml for IFNg); but the increase in these levels demonstrates the complexity of interpreting soluble biomarker levels in biologic fluids. The measured CSF cytokine levels represent the balance between their production/secretion and their binding/ uptake by target cells and tissues. In that context the small increase in cytokine levels could reflect an altered balance of production and consumption, with fewer inflammatory or activated tissue cells being able to consume/bind these cytokines.
Upon treatment with anakinra, CSF protein and albumin levels declined (7), suggesting improvement of blood-brain barrier function. The CSF cytokines IL-6, IP-10/CXCL10, and IL-18 significantly correlated with measures of blood-brain barrier function. It has been implied that these cytokines, when elevated, cause the functional changes in the endothelial cells and astrocytes layer that constitutes the blood-brain barrier and cause or aggravate blood-brain barrier dysfunction/breakdown (19, 20) . While the elevated levels of IP-10 and IL-6 suggest that they are produced intrathecally, the relatively stable IL-18 CSF:blood ratios before and after anakinra treatment and the lack of correlation between CSF IL-18 levels and WBC counts suggest that CSF IL-18 may mainly derive from passage across a "leaky" blood-brain barrier, although low levels of CNS production cannot be ruled out. Interestingly, elevations of IL-1 and IL-18 have been seen in patients with chronic tension headaches (21) , and IL-18-mediated microglia/astrocyte interactions have been associated with the development of allodynia and may play a role in development of persistent headaches (22) .
Our study is limited by the small sample size (due to the rarity of the disease) and the fact that we did not correct for the multiple exploratory analyses performed. However, serial, longitudinally collected, matched CSF and blood samples (including pretreatment CSF samples) were assayed simultaneously, which reduced interassay variability typically seen with cytokine analyses, and increases the reliability of our data interpretation. The markers we propose need to be validated in further follow-up studies and in other diseases. Multiplex cytokine assays allow for measurement of multiple cytokines simultaneously from a small sample volume, but their utility for the assessment of IL-1b and other low-expressing cytokines is limited. IL-1b is highly protein-bound; soluble serum, plasma, and CSF levels are often below 1 pg/ml, which is below the assay's detection range. Small variations in IL-1b levels can have large pathologic effects as seen in the cryopyrinopathies, but serum IL-1b measurements cannot reliably be interpreted, thus limiting their use as a biomarker. Although IL-6 is not a specific marker for inflammasome activation, it is a known downstream marker of systemic inflammation in patients with CAPS (23). In our study, IL-6 correlated best with clinical markers of CNS inflammation and may be a surrogate for assessing IL-1 activity in patients with CAPS. This is the first published study to compare treatment with 2 IL-1 blocking agents, anakinra and canakinumab, and their effects on controlling CNS inflammation in NOMID/CAPS (6 patients). CSF levels of IL-6, IP-10/CXCL10, and IL-18 and WBC counts were significantly higher when patients were being treated with canakinumab at a time when steady-state kinetics had likely been established compared to when patients were receiving anakinra treatment at steadystate kinetics. CRP levels and ESRs, and blood levels of cytokines, including IL-6, IP-10/CXCL10, and IL-18, were similar during anakinra and canakinumab treatment. However, cytokine levels in the CSF were lower when patients were receiving anakinra compared to canakinumab treatment, and there was a trend for levels to go back down when anakinra was reinitiated, in the 3 patients who began treatment with anakinra, switched to canakinumab, and then back to anakinra. Differences in CSF penetration of the 2 drugs may contribute to the differences in low-grade CNS inflammation, which may be particularly relevant in "low inflammatory states" when the blood-brain barrier is less penetrant. All patients enrolled had chronic CNS inflammation prior to receiving IL-1 blocking treatment. Our data regarding CNS inflammation cannot be extrapolated to patients with milder forms of CAPS who have lesssevere or only intermittent CNS disease.
The long-term clinical implications of chronic low elevation of CSF cytokine levels (including IL-1b, IL-6, IL-18, and IP-10) and persistently elevated monocyte counts in patients with NOMID are currently unknown, and complications from the illness can take many years to develop. Therefore, correlations with the longer-term development of symptoms and damage need to be studied in the future. Monocytes can confer proinflammatory and antiinflammatory properties (24); they play a role in wound repair and tissue surveillance and their persistence posttreatment may reflect a homeostatic adaptation (25) . Similarly, IL-6 has proand antiinflammatory properties; however, chronically elevated IL-6 levels in the CSF are seen in acute and chronic neurologic conditions (26) , and have been correlated with progression of brain atrophy in patients with neuro-Behçet's disease (27) . Elevated IL-1b levels have also been associated with Alzheimer's disease (28) and with recurrent headaches (21) . This study was not designed to investigate the long-term effects of chronic low-grade inflammation but rather was intended to identify biomarkers that may assist in the assessment and characterization of low-grade inflammation. Our data indicate the need for longitudinal assessment of patients' clinical function to determine whether the residual inflammation measured is benign or associated with long-term consequences such as headaches, cognition, and progression of brain atrophy.
In summary, our findings indicate that the regulation of inflammation in the CNS compartment cannot be predicted by blood markers of inflammation and that drugs that suppress systemic inflammation may not equally suppress CNS inflammation and suggest the value of a "personalized approach" guided by CSF biomarkers to assess residual inflammation and optimize treatment. Of the markers tested, IL-6, IL-18, and perhaps IP-10/CXCL10 may be used to monitor efficacy of IL-1 blocking therapy in controlling CNS inflammation in NOMID. Differences in blockade of CNS inflammation between anakinra and canakinumab suggest that assessment of CSF inflammation, drug penetration into the CNS, and pharmacokinetics of IL-1b inhibitors should be included when designing studies of IL-1b inhibitors in NOMID and other neuroinflammatory diseases.
